Patents by Inventor Travis Remarchuk

Travis Remarchuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158371
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Application
    Filed: October 26, 2023
    Publication date: May 16, 2024
    Inventors: Travis REMARCHUK, Anantha SUDHAKAR
  • Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Patent number: 11834438
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20220411433
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 29, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Patent number: 11427571
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: August 30, 2022
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20220249479
    Abstract: The present disclosure relates to modified release formulations of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-IH-pyrazol-1-propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts thereof, and methods of treatment with the modified release formulations.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 11, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Harish RAVIVARAPU, Travis REMARCHUK, Anantha SUDHAKAR, Bradley K. WONG
  • Patent number: 11236100
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Publication number: 20210147435
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 20, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Publication number: 20210087176
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 27, 2020
    Publication date: March 25, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20210009566
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 14, 2021
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Patent number: 10851088
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20190315723
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 17, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Patent number: 10370361
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 6, 2019
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20190194170
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 27, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Publication number: 20180258054
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Application
    Filed: October 12, 2017
    Publication date: September 13, 2018
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • Patent number: 9790190
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 17, 2017
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • Publication number: 20170247337
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 31, 2017
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • Patent number: 9676730
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: June 13, 2017
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • Publication number: 20160318877
    Abstract: The invention provides processes for preparing a compound of formula I and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 3, 2016
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: David Askin, Chong Han, Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, C. Gregory Sowell, Keith L. Spencer, Peter J. Stengel
  • Patent number: 9481690
    Abstract: The present invention relates to crystalline polymorphs of (2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (GDC-0032, taselisib), methods of use, and processes of preparing thereof.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 1, 2016
    Assignee: Genentech, Inc.
    Inventors: Jeffrey Stults, Travis Remarchuk, Frederic St-Jean